<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01872611</url>
  </required_header>
  <id_info>
    <org_study_id>C-12-071</org_study_id>
    <secondary_id>2013-001874-12</secondary_id>
    <nct_id>NCT01872611</nct_id>
  </id_info>
  <brief_title>Nepafenac Once Daily for Macular Edema - Study 2</brief_title>
  <official_title>Randomized, Double-Masked, Vehicle Controlled, Clinical Evaluation To Assess The Safety And Efficacy Of Nepafenac Ophthalmic Suspension, 0.3% For Improvement In Clinical Outcomes Among Diabetic Subjects Following Cataract Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate superiority of Nepafenac Ophthalmic Suspension,
      0.3% dosed once daily relative to Nepafenac Vehicle based upon clinical outcomes among
      diabetic participants following cataract surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Best-corrected Visual Acuity (BCVA) Improvement of ≥ 15 Letters From Preoperative Baseline to Day 14 and Maintained Through Day 90</measure>
    <time_frame>Baseline to Day 14, and maintained through Day 90</time_frame>
    <description>BCVA (with spectacles or other visual corrective devices) was reported in letters read correctly, using the Early Treatment Diabetic Retinopathy Study (ETDRS) test of 70 letters. Improvement of BCVA was defined as an increase (gain) in the number of letters read, compared to the baseline assessment. One eye (study eye) contributed to the analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Develop Macular Edema Within 90 Days Following Cataract Surgery (Day 0)</measure>
    <time_frame>Day 0 to Day 90</time_frame>
    <description>Macular edema was defined as ≥ 30% Increase from pre-operative baseline in central subfield macular thickness, as measured with Spectral Domain Ocular Coherence Tomography (SD-OCT). One eye (study eye) contributed to the analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With BCVA Improvement of ≥ 15 Letters From Preoperative Baseline to Day 90</measure>
    <time_frame>Baseline to Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With BCVA Improvement of ≥ 15 Letters From Preoperative Baseline to Day 60</measure>
    <time_frame>Baseline to Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a &gt; 5-letter Loss in BCVA From Day 7 to Any Visit</measure>
    <time_frame>Day 7 up to any visit through Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With With a &gt; 10-letter Loss in BCVA From Day 7 to Any Visit</measure>
    <time_frame>Day 7 up to any visit through Day 90</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">819</enrollment>
  <condition>Non-Proliferative Diabetic Retinopathy</condition>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>Nepafenac</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>With prednisolone acetate standard of care, Nepafenac Ophthalmic Suspension, 0.3%, 1 drop instilled in the operative eye 1 day prior to surgery, continuing on the day of surgery, and for 90 days following surgery. An additional 1 drop will be administered 30 to 120 minutes prior to surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>With prednisolone acetate standard of care, Nepafenac vehicle, 1 drop instilled in the operative eye 1 day prior to surgery, continuing on the day of surgery, and for 90 days following surgery. An additional 1 drop will be administered 30 to 120 minutes prior to surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nepafenac Ophthalmic Suspension, 0.3%</intervention_name>
    <arm_group_label>Nepafenac</arm_group_label>
    <other_name>Test intervention</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Inactive ingredients used as placebo comparator</description>
    <arm_group_label>Vehicle</arm_group_label>
    <other_name>Nepafenac Vehicle</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone acetate</intervention_name>
    <description>1 drop instilled in the operative eye 4 times daily beginning post-operatively on the day of surgery for the first 2 weeks, followed by 2 times daily for the next 2 weeks</description>
    <arm_group_label>Nepafenac</arm_group_label>
    <arm_group_label>Vehicle</arm_group_label>
    <other_name>Omnipred™</other_name>
    <other_name>Prednisolone acetate ophthalmic suspension</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Planned cataract extraction by phacoemulsification with implantation of a posterior
             chamber intraocular lens;

          -  History of Type 1 or 2 diabetes and non-proliferative diabetic retinopathy (NPDR)
             (mild, moderate, or severe) in the study eye;

          -  Best-corrected visual acuity (BCVA) of 73 letters or worse in the study eye with
             expectation of improvement after surgery;

          -  Understand and sign an informed consent document;

          -  Other protocol-defined inclusion criteria may apply.

        Exclusion Criteria:

          -  Pre-existing macular edema in the study eye;

          -  History in the study eye of retinal detachment, wet age-related macular degeneration,
             chronic or recurrent inflammatory eye disease, or prior procedures;

          -  Planned cataract surgery in the fellow eye prior to the Day 90 postoperative study
             visit or through study exit;

          -  Planned multiple procedures for the study eye during the cataract/intraocular lens;

          -  Use of exclusionary medications, including nonsteroidal anti-inflammatory drugs
             (NSAIDs) and steroids, as specified in protocol.

          -  Participation in any other clinical study within 30 days of the screening visit;

          -  Females of childbearing potential who are breast feeding, have a positive urine
             pregnancy test at screening, are not willing to undergo a urine pregnancy test upon
             entering or exiting the study, intend to become pregnant during the study, or do not
             agree to use adequate birth control methods for the duration of the study;

          -  Other protocol-defined exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Project Lead GCRA, Pharma</last_name>
    <role>Study Director</role>
    <affiliation>Alcon Research</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2013</study_first_submitted>
  <study_first_submitted_qc>June 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2013</study_first_posted>
  <results_first_submitted>May 24, 2016</results_first_submitted>
  <results_first_submitted_qc>June 22, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 2, 2016</results_first_posted>
  <last_update_submitted>June 22, 2016</last_update_submitted>
  <last_update_submitted_qc>June 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Type I</keyword>
  <keyword>Diabetes Type II</keyword>
  <keyword>Non-proliferative diabetic retinopathy</keyword>
  <keyword>Macular edema</keyword>
  <keyword>Cataract</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Nepafenac</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from 73 investigational centers located in the U.S., Europe, the Middle East, Africa, Latin America, the Caribbean, and the Asia Pacific region.</recruitment_details>
      <pre_assignment_details>Of the 819 participants enrolled, 191 were exited as screen failures and 23 were discontinued prior to randomization. This reporting group includes all randomized participants (605).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Nepafenac</title>
          <description>Nepafenac Ophthalmic Suspension, 0.3%</description>
        </group>
        <group group_id="P2">
          <title>Vehicle</title>
          <description>Nepafenac Ophthalmic Suspension Vehicle</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="301"/>
                <participants group_id="P2" count="304"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Randomized</title>
              <participants_list>
                <participants group_id="P1" count="301"/>
                <participants group_id="P2" count="304"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated (Safety Analysis Set)</title>
              <participants_list>
                <participants group_id="P1" count="293"/>
                <participants group_id="P2" count="295"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="289"/>
                <participants group_id="P2" count="293"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="277"/>
                <participants group_id="P2" count="292"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event, prior to treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death, prior to treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason not provided</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full analysis set, defined as all randomized participants who completed implant surgery and had at least one on-therapy postsurgical visit.</population>
      <group_list>
        <group group_id="B1">
          <title>Nepafenac</title>
          <description>Nepafenac Ophthalmic Suspension, 0.3%</description>
        </group>
        <group group_id="B2">
          <title>Vehicle</title>
          <description>Nepafenac Ophthalmic Suspension Vehicle</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="289"/>
            <count group_id="B2" value="293"/>
            <count group_id="B3" value="582"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.7" spread="8.5"/>
                    <measurement group_id="B2" value="68.1" spread="8.4"/>
                    <measurement group_id="B3" value="67.9" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="149"/>
                    <measurement group_id="B2" value="149"/>
                    <measurement group_id="B3" value="298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="140"/>
                    <measurement group_id="B2" value="144"/>
                    <measurement group_id="B3" value="284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Best-corrected Visual Acuity (BCVA) Improvement of ≥ 15 Letters From Preoperative Baseline to Day 14 and Maintained Through Day 90</title>
        <description>BCVA (with spectacles or other visual corrective devices) was reported in letters read correctly, using the Early Treatment Diabetic Retinopathy Study (ETDRS) test of 70 letters. Improvement of BCVA was defined as an increase (gain) in the number of letters read, compared to the baseline assessment. One eye (study eye) contributed to the analysis.</description>
        <time_frame>Baseline to Day 14, and maintained through Day 90</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Nepafenac</title>
            <description>Nepafenac Ophthalmic Suspension, 0.3%</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Nepafenac Ophthalmic Suspension Vehicle</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Best-corrected Visual Acuity (BCVA) Improvement of ≥ 15 Letters From Preoperative Baseline to Day 14 and Maintained Through Day 90</title>
          <description>BCVA (with spectacles or other visual corrective devices) was reported in letters read correctly, using the Early Treatment Diabetic Retinopathy Study (ETDRS) test of 70 letters. Improvement of BCVA was defined as an increase (gain) in the number of letters read, compared to the baseline assessment. One eye (study eye) contributed to the analysis.</description>
          <population>Full analysis set</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="289"/>
                <count group_id="O2" value="293"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.8"/>
                    <measurement group_id="O2" value="50.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This endpoint was considered primary for United States (US) registration and secondary for European Union (EU) registration.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.671</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
            <estimate_desc>Parameter dispersion is the standard error for the odds ratio.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Develop Macular Edema Within 90 Days Following Cataract Surgery (Day 0)</title>
        <description>Macular edema was defined as ≥ 30% Increase from pre-operative baseline in central subfield macular thickness, as measured with Spectral Domain Ocular Coherence Tomography (SD-OCT). One eye (study eye) contributed to the analysis.</description>
        <time_frame>Day 0 to Day 90</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Nepafenac</title>
            <description>Nepafenac Ophthalmic Suspension, 0.3%</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Nepafenac Ophthalmic Suspension Vehicle</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Develop Macular Edema Within 90 Days Following Cataract Surgery (Day 0)</title>
          <description>Macular edema was defined as ≥ 30% Increase from pre-operative baseline in central subfield macular thickness, as measured with Spectral Domain Ocular Coherence Tomography (SD-OCT). One eye (study eye) contributed to the analysis.</description>
          <population>Full analysis set</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="289"/>
                <count group_id="O2" value="293"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9"/>
                    <measurement group_id="O2" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This endpoint was considered primary for EU registration and secondary for US registration.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.2</ci_lower_limit>
            <ci_upper_limit>0.7</ci_upper_limit>
            <estimate_desc>Parameter dispersion is the standard error for the odds ratio.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With BCVA Improvement of ≥ 15 Letters From Preoperative Baseline to Day 90</title>
        <time_frame>Baseline to Day 90</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Nepafenac</title>
            <description>Nepafenac Ophthalmic Suspension, 0.3%</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Nepafenac Ophthalmic Suspension Vehicle</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With BCVA Improvement of ≥ 15 Letters From Preoperative Baseline to Day 90</title>
          <population>Full analysis set</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="289"/>
                <count group_id="O2" value="293"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.4"/>
                    <measurement group_id="O2" value="65.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With BCVA Improvement of ≥ 15 Letters From Preoperative Baseline to Day 60</title>
        <time_frame>Baseline to Day 60</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Nepafenac</title>
            <description>Nepafenac Ophthalmic Suspension, 0.3%</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Nepafenac Ophthalmic Suspension Vehicle</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With BCVA Improvement of ≥ 15 Letters From Preoperative Baseline to Day 60</title>
          <population>Full analysis set</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="289"/>
                <count group_id="O2" value="293"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.9"/>
                    <measurement group_id="O2" value="62.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a &gt; 5-letter Loss in BCVA From Day 7 to Any Visit</title>
        <time_frame>Day 7 up to any visit through Day 90</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Nepafenac</title>
            <description>Nepafenac Ophthalmic Suspension, 0.3%</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Nepafenac Ophthalmic Suspension Vehicle</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a &gt; 5-letter Loss in BCVA From Day 7 to Any Visit</title>
          <population>Full analysis set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="289"/>
                <count group_id="O2" value="293"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.7"/>
                    <measurement group_id="O2" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With With a &gt; 10-letter Loss in BCVA From Day 7 to Any Visit</title>
        <time_frame>Day 7 up to any visit through Day 90</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Nepafenac</title>
            <description>Nepafenac Ophthalmic Suspension, 0.3%</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Nepafenac Ophthalmic Suspension Vehicle</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With With a &gt; 10-letter Loss in BCVA From Day 7 to Any Visit</title>
          <population>Full analysis set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="289"/>
                <count group_id="O2" value="293"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7"/>
                    <measurement group_id="O2" value="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Reporting of adverse events (AEs) began once informed consent was obtained and continued through Day 90 (or Day 120, if unresolved macular edema present at Day 90). Ocular adverse events are presented for both study eye and nonstudy eye combined.</time_frame>
      <desc>An AE was defined as any untoward medical occurrence in a participant after signing the informed consent and did not necessarily have to have a causal relationship with the study treatment. AEs were reported as pretreatment, treatment-emergent, and posttreatment. AEs were obtained through solicited and spontaneous comments from the participants.</desc>
      <group_list>
        <group group_id="E1">
          <title>Pretreatment</title>
          <description>All participants who consented to participate in the study prior to the initiation of study treatment</description>
        </group>
        <group group_id="E2">
          <title>Nepafenac</title>
          <description>Nepafenac Ophthalmic Suspension, 0.3%</description>
        </group>
        <group group_id="E3">
          <title>Vehicle</title>
          <description>Nepafenac Ophthalmic Suspension Vehicle</description>
        </group>
        <group group_id="E4">
          <title>Posttreatment</title>
          <description>All participants after cessation of study treatment up to study exit</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (16.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="819"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="293"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="588"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="819"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="588"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="819"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="588"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="819"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="588"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="819"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="588"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="819"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="588"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="819"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="588"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="819"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="588"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic retinal oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="819"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="588"/>
              </event>
              <event>
                <sub_title>Optic ischaemic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="819"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="588"/>
              </event>
              <event>
                <sub_title>Posterior capsule rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="819"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="588"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="819"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="588"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="819"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="588"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="819"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="588"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="819"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="588"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="819"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="588"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="819"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="588"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="819"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="588"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="819"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="588"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="819"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="588"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="819"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="588"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="819"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="588"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="819"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="588"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="819"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="588"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="819"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="588"/>
              </event>
              <event>
                <sub_title>Vertebral foraminal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="819"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="588"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="819"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="293"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="588"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="819"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="588"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="819"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="588"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="819"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="588"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="819"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="588"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Arteriovenous fistula operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="819"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="588"/>
              </event>
              <event>
                <sub_title>Cardiac operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="819"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="588"/>
              </event>
              <event>
                <sub_title>Cataract operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="819"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="588"/>
              </event>
              <event>
                <sub_title>Intra-ocular injection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="819"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="588"/>
              </event>
              <event>
                <sub_title>Skin graft</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="819"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="588"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="819"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="588"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="819"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="588"/>
              </event>
              <event>
                <sub_title>Peripheral artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="819"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="588"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="819"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="588"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="819"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="588"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor reserves the right of prior review of any publication or presentation of information related to the study.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Unit Head, Cornea and Inflammation</name_or_title>
      <organization>Alcon Research, Ltd.</organization>
      <phone>1-888-451-3937</phone>
      <email>alcon.medinfo@alcon.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

